This stock no longer trades (delisted March 15, 2025)

Delisted / no longer publicly traded (per market data provider) Everything below is based on the last available data — treat it as historical, not a live read.

Stock

AmerisourceBergen Corporation

ABC
52
Medical - Distribution · Healthcare
Price
$179.98
-0.41 (-0.23%)
Market Cap
$36.15B
Exchange
New York Stock Exchange
Winston Score
52
Historical score — this stock no longer trades, so the score is frozen at the last available data.
Data as of Oct 18, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
12/30
Growth
Good
13/20
Cash Flow
Strong
7/10
Stability
Mixed
3/10
Valuation
Good
5/10
Ownership
Good
10/15
Dividends
Mixed
2/5

52 of 100 counted points = Winston Score 52.

Share count falling — buybacks

−6.4% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 208.5M (2021) → 195.2M (2025)

§Winston Score History

The full picture

AmerisourceBergen, now operating under the name Cencora, is one of the largest pharmaceutical distribution companies in the world. It buys medicines and healthcare products from drug manufacturers and delivers them to pharmacies, hospitals, and doctors' offices across the United States and internationally. It serves as a critical middleman in the healthcare supply chain, handling billions of dollars worth of drugs each year.

The company makes money by purchasing pharmaceuticals in bulk and selling them to healthcare providers at a small markup, which explains its very thin margins on enormous revenue. It operates primarily in the U.S. but has a growing international presence, especially after acquiring Alliance Healthcare. Its massive scale and established relationships with manufacturers and customers create a strong competitive position that is difficult for newcomers to replicate. Key growth drivers include specialty drug distribution and international expansion, while ongoing opioid-related litigation remains a notable risk.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+5.1% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+11.3% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

15.6%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$2.8B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

AmerisourceBergen Corporation is growing revenue at 5% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
4.3%
Thin — 4.3% gross margin
Profit after running costs
Operating Margin
1.3%
Thin — 1.3% operating margin
Return on the money invested
ROCE
20.6%
Exceptional — 20.6% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+2.9%
Nearly flat sales (+2.9% YoY)
Profit growth
EPS YoY
+31.3%
Earnings growing fast (+31.3% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
184%
Turns 184% of profit into real cash
Spare cash per sale
FCF Margin
1.2%
Thin free cash flow (1.2%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
3.84
Heavy debt load (3.84)
Covers its interest
Interest Cover
6.83x
Adequate interest coverage (6.8x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
13.3x
Attractive valuation — P/E 13.3

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
1.08%
Small dividend — 1.08% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record
Dividend Growth
+5.4%
Dividend growing modestly (5.4% YoY)
Payout Ratio
18%
no trend
Pays out a modest share of profit and keeps the rest to reinvest. Room to keep paying through a weak year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial